gave the look of DermacinRx FoliPlus D member of the family

expecting DermacinRx FoliPlus D merchant
 
Photo :DermacinRx FoliPlus D

giving freely DermacinRx FoliPlus D Generic Name: folic acid, vitamin d3 Dosage Form: capsule, liquid filled Print this page Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. DermacinRx FoliPlus D Description FoliPlus D is an orally administered prescription folate product for the dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation due to Vitamin D deficiency. FoliPlus D should be administered under the supervision of a licensed medical practitioner. Each softgel contains: Folic Acid ..........................................................................1 mg Vitamin D 3 (cholecalciferol) ......................................3333 IU Each softgel contains the following inactive ingredients: polyethylene glycol, gelatin, glycerin, corn oil, yellow 10 (ci 47005), titanium dioxide. INDICATIONS AND DOSAGE FoliPlus D is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation. FoliPlus D can be taken by women of childbearing age, pregnant women, and lactating and nonlactating mothers. DermacinRx FoliPlus D - Clinical Pharmacology The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules. There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys. Contraindications This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. FoliPlus D is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D. Warnings and Precautions KEEP OUT OF THE REACH OF CHILDREN. Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breast-feeding. Consult your doctor about the risks and benefits. Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B 12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress. ADVERSE REACTIONS Allergic sensitization has been reported following both oral and parenteral administration of folic acid. You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact PureTek Corporation, at 1-877-921-7873. DermacinRx FoliPlus D Dosage and Administration Take one softgel daily or as directed by a healthcare practitioner. How is DermacinRx FoliPlus D Supplied FoliPlus D is supplied as oval, light yellow translucent softgels and dispensed in child-resistant bottles of 30 softgels (NDC 59088-128-54*). * This product is a prescription-folate with or without other dietary ingredients that due to increased folate levels (AUG 2 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of B 12 deficiency (pernicious anemia). Based on our assessment of the risk of obscuring pernicious anemia, this product requires licensed medical supervision, an Rx status, and a National Drug Code (NDC) or similarly-formatted product code, as required by pedigree reporting requirements and supply-chain control as well as in some cases, for insurance-reimbursement applications. All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician s supervision. There are no implied or explicit claims on therapeutic equivalence. STORAGE KEEP OUT OF THE REACH OF CHILDREN. Store at 20 -25 C (68 -77 F); excursions permitted to 15 -30 C (59 -86 F) [see USP Controlled Room Temperature]. Protect from heat, light and moisture. Tamper Evident: Do not use if seal is broken or missing Manufactured in the USA by: PureTek Corporation San Fernando, CA 91340 For questions or information call toll-free: 877-921-7873 Visit: dermacinrx.com Rev. 37809 07/16 PACKAGE LABEL / PRINCIPAL DISPLAY PANEL Bottle Label (30 Tablets) DERMACINRX FOLIPLUS D folic acid, vitamin d3 capsule, liquid filled Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:59088-128 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength FOLIC ACID (FOLIC ACID) FOLIC ACID 1 mg VITAMIN D (CHOLECALCIFEROL) VITAMIN D 83.325 ug Inactive Ingredients Ingredient Name Strength POLYETHYLENE GLYCOL 400 GELATIN GLYCERIN CORN OIL D&C YELLOW NO. 10 TITANIUM DIOXIDE Product Characteristics Color yellow Score no score Shape OVAL Size 4mm Flavor Imprint Code Contains Packaging # Item Code Package Description 1 NDC:59088-128-54 30 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 07/15/2016 Labeler - PureTek Corporation (785961046) Revised: 07/2016 PureTek Corporation FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Recently Approved Lonhala Magnair Lonhala Magnair (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator for... Ozempic Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the... Ogivri Ogivri (trastuzumab-dkst) is a HER2 / neu receptor antagonist biosimilar to Herceptin indicated for... Sublocade Sublocade (buprenorphine) is a once-monthly injectable partial opioid agonist formulation for the... More keep in mind that


place of work DermacinRx FoliPlus D footage


EmoticonEmoticon